| Texto completo | |
| Autor(es): |
Fukumori, Claudio
;
Kawassaki, Rodrigo Ken
;
Dare, Regina G.
;
Lopes, Luciana B.
Número total de Autores: 4
|
| Tipo de documento: | Artigo Científico |
| Fonte: | International Journal of Pharmaceutics; v. 676, p. 15-pg., 2025-04-16. |
| Resumo | |
Colorectal cancer (CRC) is the third most frequent cancer worldwide. Despite advances in treatment, conventional chemotherapy suffers from severe side effects and limited drug selectivity, highlighting the importance of alternative therapies. In this study, a polymer-lipid hybrid microcarrier was developed for oral co-administration of paclitaxel (PTX) and tributyrin (TB) as a novel approach for CRC therapy. The microcarrier was designed with a pH-sensitive polymeric shell that encapsulates drug-loaded nanostructured lipid carriers (NLC); shell dissolution at intestinal pH enables localized release of the NLC. The methodological approach employed an emulsion of vegetable oil and NLC as a template for polymer deposition. Multiple parameters were optimized, including polymers ratios, NLC dilution, acid concentration, and sonication time. Spherical hybrid particles with smooth surface and mean size of 1000 nm were obtained; PTX encapsulation efficiency was 99.9 +/- 0.2 %, with a production yield of 97.2 +/- 0.08 %. Drug release followed the Korsmeyer-Peppas kinetic model. Cytotoxic evaluation in human colorectal adenocarcinoma HCT-116 monolayers showed that PTX encapsulation increased cytotoxicity, lowering IC50 to 83.7 nM compared to 199.5 nM for free PTX. The addition of TB further improved cytotoxicity, reducing the IC50 to 60.8 nM. A similar potentiation cytotoxicity was observed in spheroids. The microcarrier induced reductions in colony formation, alterations in cell cytoskeleton, and led to a significant reduction in P-glycoprotein expression compared to its free form, suggesting its potential to help to overcome drug resistance. These results point to the promising applicability of the hybrid microcarrier as an innovative delivery system for oral administration of cytotoxic agents. (AU) | |
| Processo FAPESP: | 22/12876-7 - Estudo de sistemas de pectina-quitosana enriquecidos com carreadores lipídicos nanoestruturados para a veiculação de nisina, sinvastatina e adenosina visando ao tratamento de úlceras cutâneas |
| Beneficiário: | Regina Gomes Daré |
| Modalidade de apoio: | Bolsas no Brasil - Pós-Doutorado |
| Processo FAPESP: | 19/03241-5 - Desenvolvimento e avaliação de nanocarreadores orais contendo 5-fluorouracil e metabólitos intestinais |
| Beneficiário: | Claudio Fukumori |
| Modalidade de apoio: | Bolsas no Brasil - Doutorado |
| Processo FAPESP: | 19/02151-2 - Desenvolvimento de nanoagente teranóstico bimodal para MRI e PET/SPECT |
| Beneficiário: | Rodrigo Ken Kawassaki |
| Modalidade de apoio: | Bolsas no Brasil - Doutorado Direto |
| Processo FAPESP: | 19/21910-1 - EMU concedido no processo 2018/13877-1: equipamento para cromatografia líquida de alta eficiência (HPLC) |
| Beneficiário: | Luciana Biagini Lopes |
| Modalidade de apoio: | Auxílio à Pesquisa - Programa Equipamentos Multiusuários |
| Processo FAPESP: | 14/50928-2 - INCT 2014: Nanotecnologia Farmacêutica: uma abordagem transdisciplinar |
| Beneficiário: | Maria Vitória Lopes Badra Bentley |
| Modalidade de apoio: | Auxílio à Pesquisa - Temático |
| Processo FAPESP: | 18/13877-1 - Nanocarreadores para a quimioprevenção e tratamento localizado de tumores de mama |
| Beneficiário: | Luciana Biagini Lopes |
| Modalidade de apoio: | Auxílio à Pesquisa - Jovens Pesquisadores - Fase 2 |